Humacyte, Inc.
NASDAQ:HUMABiotechnology
Healthcare
$0.50 -3.35%
-$0.03 today
- Market cap
- $139.18M
- Beta
- 2.46
- P/E (TTM)
- -1.9
- EPS (TTM)
- -$0.49
52W Low $0.55High $2.84
Volume 4.34M
Average 8.14M
Income Statement
Follow revenue through to earnings.
Revenue
$2.04M
FY 2025 · Annual
Operating Income
-$107.44M
FY 2025 · Annual
Net Income
-$40.83M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.26M | 1.57M | 0 | 0 | 2.04M |
| Cost of Revenue | 61.34M | 8.26M | 76.55M | 7.19M | 17.05M |
| Gross Profit | (60.08M) | (6.69M) | (76.55M) | (7.19M) | (15.01M) |
| Gross Margin | -4756.8% | -427.5% | — | — | -736.5% |
| Research & Development | 61.34M | 63.26M | 76.55M | 88.6M | 69.3M |
| Selling, General & Admin | 21.13M | 22.88M | 20.39M | 25.8M | 31.17M |
| Operating Expenses | 21.13M | 77.89M | 23.5M | 107.21M | 92.43M |
| Depreciation & Amortization | 8.24M | 8.21M | 7.72M | 7.19M | 7.35M |
| EBITDA | (13.89M) | 2.45M | (96.46M) | (132.23M) | (22.24M) |
| EBITDA Margin | -1099.6% | 156.2% | — | — | -1091.2% |
| Operating Income | (81.21M) | (84.58M) | (100.05M) | (114.4M) | (107.44M) |
| Operating Margin | -6429.8% | -5404.3% | — | — | -5271.7% |
| Interest Income | 16K | 2.63M | 5.47M | 4.1M | 2.59M |
| Interest Expense | 4.35M | 6.2M | 6.6M | 9.28M | 11.25M |
| Other Income / Expenses | 54.73M | 72.61M | (10.73M) | (34.3M) | 66.6M |
| Income Before Tax | (26.48M) | (11.97M) | (110.78M) | (148.7M) | (40.83M) |
| Pre-Tax Margin | -2096.4% | -764.5% | — | — | -2003.6% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (26.48M) | (11.97M) | (110.78M) | (148.7M) | (40.83M) |
| Net Margin | -2096.4% | -764.5% | — | — | -2003.6% |
| EPS (Basic) | (0.66) | (0.12) | (1.07) | (1.26) | (0.26) |
| EPS (Diluted) | (0.66) | (0.12) | (1.07) | (1.26) | (0.26) |
| 39.97M | 103.05M | 103.42M | 118.48M | 158.16M | |
| 39.97M | 103.05M | 103.42M | 118.48M | 158.16M |
HUMA Earnings Waterfall · TTM
NASDAQ:HUMA · Revenue to Net Income
Key Ratios
EPS$-0.59
Gross Margin-827.6%
Net Margin-5926.8%
P/E Ratio-2.3
P/S Ratio503.2
Analysis
$2.0M of revenue converted into -$97.6M of net income for the selected period. Gross margin is -827.6% and net margin is -5926.8%, showing how much revenue survives after costs and taxes. EPS is $-0.59, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 10, 2026 | |
| 8-K | Current report | Nov 10, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 7, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 7, 2026 | |
| 3 | Initial statement of beneficial ownership | Sep 28, 2026 |
How much revenue does HUMA generate?
Humacyte, Inc. (HUMA) reported $2.04M of revenue in fiscal 2025.
Is HUMA profitable?
Humacyte, Inc. (HUMA) reported -$40.83M of net income, with a net margin of -2003.6%.
Continue the stock analysis
Jump to another research area for this company.